Aurobindo Pharma has received USFDA approval to manufacture and market generic Voriconazole tablets used for the treatment of fungal infections. It expects to launch the product, generic version of PF Prism C V’s Vfend tablets in the same strengths, by March 2016. The approved product has an estimated market size of USD 103 million for the twelve months ending November 2015 . Currently, the company has 233 Abbreviated New Drug Application (ANDA) approvals, (202 final approvals including 10 from Aurolife Pharma LLC and 31 tentative approvals) from USFDA.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply